BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News

Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Defence Therapeutics Reports Reprogrammed MSC Vaccine Cures 80% of Animals with Lymphoma Cancer

By Leave a Comment

Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma

Vancouver, British Columbia, September 21, 2022 – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report that Defence’s novel vaccine candidate triggers a potent anti-tumoral response capable of curing animals with pre-established lymphoma. [Read more…]

StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy

By Leave a Comment

August 29, 2022, BALDWIN PARK, CA, — Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy. PCS is also referred to as Long COVID and is characterized by lingering health effects or symptoms that are not explained by tests, which could last years. StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair. [Read more…]

CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop “off-the-shelf” CAR-iMAC cell therapy

By Leave a Comment

Sept. 5, 2022, China, HANGZHOU  — CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy. [Read more…]

denovoMATRIX Launches Cell Therapy Grade Consumables

By Leave a Comment

DRESDEN, Germany, September. 19, 2022 /BioInformant/ — denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, announced the launch of its animal component-free product lines at cell therapy grade (CTG). The new product lines will include documentation and traceability information for compliance with industry regulatory standards, designed for the stem cell therapy manufacturing market.

[Read more…]

BioInformant's World-Class Clients